Epizyme, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 250
- Market Cap
- -
- Website
- http://www.epizyme.com
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyeloproliferative DisordersMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01684150
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇳🇱Erasmus University Medical Center, Rotterdam, Netherlands
🇺🇸Mayo Clinic Scottsdale-Phoenix, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath